Phase IV, randomized, open-label study comparing the use of Grafalon® versus Thymoglobulin® in non-sensitized patients who have received a kidney transplant at high risk of delayed graft function

Chronic Kidney Disease, Kidney transplantation

Lymphocyte values throughout follow-up.

Hemoglobin, leukocyte, neutrophil, and platelet values throughout follow-up., Number of patients requiring the use of granulopoietic colony-stimulating factors throughout follow-up., Number of patients who develop infections throughout follow-up., Number of viral, bacterial, or fungal infections in the study populations, Number of patients with repeated or recurrent infections, Number of patients requiring hospital admission for infections, Number of patients with a satisfactory or unsatisfactory course due to infectious complications., Number of patients requiring discontinuation of any of the drugs due to serious adverse effects., Number of patients in whom the remaining treatment must be modified due to adverse events associated with the use of the study drugs., Number of patients in whom maintenance immunosuppression is discontinued., Number of patients in whom prophylactic treatment is discontinued., Number of patients who develop AR in the first 3 months after transplantation, Number of patients who develop AR in the first year after transplantation, Number of cellular mediated rejection episodes, Number of episodes of antibody mediated rejection, Number of patients presenting with functioning kidney graft, Mean renal function measured by serum Cr (mg/dl), Proteinuria in 24-h urine or protein/creatinine ratio (mg/g), Number of patients who develop DGF in the immediate post-transplant period, Number of patients presenting with PGD., levels of the maintenance immunosuppressive treatment used in each case., Number of cancers during follow-up.

No related papers found yet.